<?xml version="1.0" encoding="ISO-8859-1"?><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<front>
<journal-meta>
<journal-id>2007-3380</journal-id>
<journal-title><![CDATA[Revista bio ciencias]]></journal-title>
<abbrev-journal-title><![CDATA[Revista bio ciencias]]></abbrev-journal-title>
<issn>2007-3380</issn>
<publisher>
<publisher-name><![CDATA[Universidad Autónoma de Nayarit]]></publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id>S2007-33802020000100115</article-id>
<article-id pub-id-type="doi">10.15741/revbio.07.e762</article-id>
<title-group>
<article-title xml:lang="en"><![CDATA[Different levels of expression of ALDH1A1 and DYRK1B in patients with glioblastoma multiforme and their overall survival]]></article-title>
<article-title xml:lang="es"><![CDATA[Diferentes niveles de expresión de ALDH1A1 y DYRK1B en pacientes con glioblastoma multiforme y su tiempo de sobrevida]]></article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Sánchez-Hernández]]></surname>
<given-names><![CDATA[L.]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Saavedra Sotelo]]></surname>
<given-names><![CDATA[R.]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Torres-Corona]]></surname>
<given-names><![CDATA[D. D.]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Aguirre-Quezada]]></surname>
<given-names><![CDATA[D. E.]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Gómez-García]]></surname>
<given-names><![CDATA[E.]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
</contrib-group>
<aff id="Af1">
<institution><![CDATA[,Centro Oncológico Estatal ISSEMyM Unidad de Investigación Básica y Aplicada en Salud ]]></institution>
<addr-line><![CDATA[Toluca Estado de México]]></addr-line>
<country>México</country>
</aff>
<aff id="Af2">
<institution><![CDATA[,Centro Oncológico Estatal ISSEMyM Departamento de Patología ]]></institution>
<addr-line><![CDATA[Toluca Estado de México]]></addr-line>
<country>México</country>
</aff>
<pub-date pub-type="pub">
<day>00</day>
<month>00</month>
<year>2020</year>
</pub-date>
<pub-date pub-type="epub">
<day>00</day>
<month>00</month>
<year>2020</year>
</pub-date>
<volume>7</volume>
<copyright-statement/>
<copyright-year/>
<self-uri xlink:href="http://www.scielo.org.mx/scielo.php?script=sci_arttext&amp;pid=S2007-33802020000100115&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://www.scielo.org.mx/scielo.php?script=sci_abstract&amp;pid=S2007-33802020000100115&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://www.scielo.org.mx/scielo.php?script=sci_pdf&amp;pid=S2007-33802020000100115&amp;lng=en&amp;nrm=iso"></self-uri><abstract abstract-type="short" xml:lang="en"><p><![CDATA[Abstract: Glioblastoma multiforme is the most malignant form of central nervous system astrocytoma. The overall survival median in patients with glioblastoma is 12 to 16 months after undergoing resection surgery, chemo radiotherapy and adjuvant treatment; However, it is still unclear which molecular factors are involved in the determination of overall survival. Recent reports pointed out a specific isoform of aldehyde dehydrogenase (ALDH1A1), a protein participating in cellular metabolic processes, as a potential biomarker in glioblastoma. In this study, the expression of ALDH1A1 in biopsies of glioblastoma from Mexican patients was identified and evaluated using immunohistochemical dyes, reverse transcription polymerase chain reaction (RT-PCR) and mass spectroscopy analyses. On the other hand, the presence of DYRK1B, a kinase involved in the regulation of tumor progression and in the regulation of the cell cycle was also analyzed using immunohistochemical detection and western blot. The purpose of this study was to investigate whether the histological expression, as well as the expression pattern of both proteins (ALDH1A1 and DIRK1B) presented a significant correlation with the overall survival in patients diagnosed with glioblastoma. Different expression patterns were found and both ALDH1A1 and DYRK1B showed similar expression patterns and an important correlation with the overall survival of patients. These findings allowed to consider the expression levels of ALDH1A1 and DYRK1B as possible prognostic factors in the diagnosis or possible biomarkers for survival time in patients with glioblastoma.]]></p></abstract>
<abstract abstract-type="short" xml:lang="es"><p><![CDATA[Resumen: El glioblastoma multiforme es la forma más maligna de astrocitoma del sistema nervioso central. La mediana de supervivencia global con glioblastoma es de 12 a 16 meses después de la cirugía de resección, la quimioterapia y el tratamiento adyuvante; sin embargo, aún no está claro qué factores moleculares están involucrados en la determinación de la supervivencia global. Informes recientes muestran la isoforma A1A de aldehído deshidrogenasa (ALDH1A1), una proteína que participa en los procesos metabólicos celulares, como un biomarcador potencial en glioblastoma. En este estudio, identificamos y evaluamos la presencia de ALDH1A1 en biopsias de glioblastoma de pacientes mexicanos mediante inmunohistoquímica, reacción en cadena de la polimerasa por retrotranscripción y análisis de espectroscopía de masas. Por otro lado, también analizamos mediante pruebas inmunohistoquímicas y western blot la presencia de DYRK1B, una quinasa implicada en la regulación de la progresión tumoral y en la regulación del ciclo celular. El propósito de este estudio fue investigar si la expresión histológica, así como el patrón de expresión de ambas proteínas (ALDH1A1 y DIRK1B) tuvieron una correlación relevante con la supervivencia general de los pacientes diagnosticados con glioblastoma. Encontramos diferentes patrones de expresión y observamos que tanto ALDH1A1 como DYRK1B tienen patrones de expresión muy similares entre sí y ambas mostraron una importante correlación con la supervivencia general de los pacientes. Estos hallazgos nos permiten considerar que los niveles de expresión de ALDH1A1 y DYRK1B pueden ser posibles factores pronósticos en el diagnóstico o posibles biomarcadores para el tiempo de supervivencia en pacientes con glioblastoma.]]></p></abstract>
<kwd-group>
<kwd lng="en"><![CDATA[Glioblastoma]]></kwd>
<kwd lng="en"><![CDATA[ALDH1A1]]></kwd>
<kwd lng="en"><![CDATA[DYRK1B]]></kwd>
<kwd lng="en"><![CDATA[survival time]]></kwd>
<kwd lng="en"><![CDATA[immunohistochemistry]]></kwd>
<kwd lng="en"><![CDATA[mass spectrometry]]></kwd>
<kwd lng="es"><![CDATA[Glioblastoma]]></kwd>
<kwd lng="es"><![CDATA[ALDH1A1]]></kwd>
<kwd lng="es"><![CDATA[DYRK1B]]></kwd>
<kwd lng="es"><![CDATA[tiempo de supervivencia]]></kwd>
<kwd lng="es"><![CDATA[inmunohistoquímica]]></kwd>
<kwd lng="es"><![CDATA[espectrometría de masas]]></kwd>
</kwd-group>
</article-meta>
</front><back>
<ref-list>
<ref id="B1">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Aebersold]]></surname>
<given-names><![CDATA[R.]]></given-names>
</name>
<name>
<surname><![CDATA[Mann]]></surname>
<given-names><![CDATA[M.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Mass spectrometry-based proteomics]]></article-title>
<source><![CDATA[Nature]]></source>
<year>2003</year>
<volume>422</volume>
<numero>6928</numero>
<issue>6928</issue>
<page-range>198-207</page-range></nlm-citation>
</ref>
<ref id="B2">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Alexandra Adam]]></surname>
<given-names><![CDATA[S.]]></given-names>
</name>
<name>
<surname><![CDATA[Schnell]]></surname>
<given-names><![CDATA[O.]]></given-names>
</name>
<name>
<surname><![CDATA[Pöschl]]></surname>
<given-names><![CDATA[J.]]></given-names>
</name>
<name>
<surname><![CDATA[Eigenbrod]]></surname>
<given-names><![CDATA[S.]]></given-names>
</name>
<name>
<surname><![CDATA[Kretzschmar]]></surname>
<given-names><![CDATA[H. A.]]></given-names>
</name>
<name>
<surname><![CDATA[Tonn]]></surname>
<given-names><![CDATA[J. C.]]></given-names>
</name>
<name>
<surname><![CDATA[Schüller]]></surname>
<given-names><![CDATA[U.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[ALDH1A1 is a marker of astrocytic differentiation during brain development and correlates with better survival in glioblastoma patients]]></article-title>
<source><![CDATA[Brain Pathology]]></source>
<year>2012</year>
<volume>22</volume>
<numero>6</numero>
<issue>6</issue>
<page-range>788-97</page-range></nlm-citation>
</ref>
<ref id="B3">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Arnold]]></surname>
<given-names><![CDATA[S. L.]]></given-names>
</name>
<name>
<surname><![CDATA[Kent]]></surname>
<given-names><![CDATA[T.]]></given-names>
</name>
<name>
<surname><![CDATA[Hogarth]]></surname>
<given-names><![CDATA[C. A.]]></given-names>
</name>
<name>
<surname><![CDATA[Schlatt]]></surname>
<given-names><![CDATA[S.]]></given-names>
</name>
<name>
<surname><![CDATA[Prasad]]></surname>
<given-names><![CDATA[B.]]></given-names>
</name>
<name>
<surname><![CDATA[Haenisch]]></surname>
<given-names><![CDATA[M.]]></given-names>
</name>
<name>
<surname><![CDATA[Isoherranen]]></surname>
<given-names><![CDATA[N.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Importance of ALDH1A enzymes in determining human testicular retinoic acid concentrations]]></article-title>
<source><![CDATA[Journal of Lipid Research]]></source>
<year>2015</year>
<volume>56</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>342-57</page-range></nlm-citation>
</ref>
<ref id="B4">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Ashford]]></surname>
<given-names><![CDATA[A. L.]]></given-names>
</name>
<name>
<surname><![CDATA[Oxley]]></surname>
<given-names><![CDATA[D.]]></given-names>
</name>
<name>
<surname><![CDATA[Kettle]]></surname>
<given-names><![CDATA[J.]]></given-names>
</name>
<name>
<surname><![CDATA[Hudson]]></surname>
<given-names><![CDATA[K.]]></given-names>
</name>
<name>
<surname><![CDATA[Guichard]]></surname>
<given-names><![CDATA[S.]]></given-names>
</name>
<name>
<surname><![CDATA[Cook]]></surname>
<given-names><![CDATA[S. J.]]></given-names>
</name>
<name>
<surname><![CDATA[Lochhead]]></surname>
<given-names><![CDATA[P. A.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[A novel DYRK1B inhibitor AZ191 demonstrates that DYRK1B acts independently of GSK3&#946; to phosphorylate cyclin D1 at Thr 286 , not Thr 288]]></article-title>
<source><![CDATA[Biochemical Journal]]></source>
<year>2014</year>
<volume>457</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>43-56</page-range></nlm-citation>
</ref>
<ref id="B5">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Bonin]]></surname>
<given-names><![CDATA[S.]]></given-names>
</name>
<name>
<surname><![CDATA[Stanta]]></surname>
<given-names><![CDATA[G.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Nucleic acid extraction methods from fixed and paraffin-embedded tissues in cancer diagnostics]]></article-title>
<source><![CDATA[Expert Review of Molecular Diagnostics]]></source>
<year>2013</year>
<volume>13</volume>
<page-range>271-82</page-range></nlm-citation>
</ref>
<ref id="B6">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Chen]]></surname>
<given-names><![CDATA[Y.]]></given-names>
</name>
<name>
<surname><![CDATA[Wang]]></surname>
<given-names><![CDATA[S.]]></given-names>
</name>
<name>
<surname><![CDATA[He]]></surname>
<given-names><![CDATA[Z.]]></given-names>
</name>
<name>
<surname><![CDATA[Sun]]></surname>
<given-names><![CDATA[F.]]></given-names>
</name>
<name>
<surname><![CDATA[Huang]]></surname>
<given-names><![CDATA[Y.]]></given-names>
</name>
<name>
<surname><![CDATA[Ni]]></surname>
<given-names><![CDATA[Q.]]></given-names>
</name>
<name>
<surname><![CDATA[Cheng]]></surname>
<given-names><![CDATA[C.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[DYRK1B overexpression is associated with breast cancer growth and a poor prognosis]]></article-title>
<source><![CDATA[Human Pathology]]></source>
<year>2017</year>
<volume>66</volume>
<page-range>48-58</page-range></nlm-citation>
</ref>
<ref id="B7">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Cheng]]></surname>
<given-names><![CDATA[P.]]></given-names>
</name>
<name>
<surname><![CDATA[Wang]]></surname>
<given-names><![CDATA[J.]]></given-names>
</name>
<name>
<surname><![CDATA[Waghmare]]></surname>
<given-names><![CDATA[I.]]></given-names>
</name>
<name>
<surname><![CDATA[Sartini]]></surname>
<given-names><![CDATA[S.]]></given-names>
</name>
<name>
<surname><![CDATA[Coviello]]></surname>
<given-names><![CDATA[V.]]></given-names>
</name>
<name>
<surname><![CDATA[Zhang]]></surname>
<given-names><![CDATA[Z.]]></given-names>
</name>
<name>
<surname><![CDATA[Nakano]]></surname>
<given-names><![CDATA[I.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[FOXD1-ALDH1A3 signaling is a determinant for the self-renewal and tumorigenicity of mesenchymal glioma stem cells]]></article-title>
<source><![CDATA[Cancer Research]]></source>
<year>2016</year>
<volume>76</volume>
<numero>24</numero>
<issue>24</issue>
<page-range>7219-30</page-range></nlm-citation>
</ref>
<ref id="B8">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Deng]]></surname>
<given-names><![CDATA[X.]]></given-names>
</name>
<name>
<surname><![CDATA[Ewton]]></surname>
<given-names><![CDATA[D. Z.]]></given-names>
</name>
<name>
<surname><![CDATA[Li]]></surname>
<given-names><![CDATA[S.]]></given-names>
</name>
<name>
<surname><![CDATA[Naqvi]]></surname>
<given-names><![CDATA[A.]]></given-names>
</name>
<name>
<surname><![CDATA[Mercer]]></surname>
<given-names><![CDATA[S. E.]]></given-names>
</name>
<name>
<surname><![CDATA[Landas]]></surname>
<given-names><![CDATA[S.]]></given-names>
</name>
<name>
<surname><![CDATA[Friedman]]></surname>
<given-names><![CDATA[E.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[The kinase Mirk/DYRK1B mediates cell survival in pancreatic ductal adenocarcinoma]]></article-title>
<source><![CDATA[Cancer Research]]></source>
<year>2006</year>
<volume>66</volume>
<numero>8</numero>
<issue>8</issue>
<page-range>4149-58</page-range></nlm-citation>
</ref>
<ref id="B9">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Friedman]]></surname>
<given-names><![CDATA[E.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[MIRK/DYRK1B kinase in ovarian cancer]]></article-title>
<source><![CDATA[International Journal of Molecular Sciences]]></source>
<year>2013</year>
<volume>14</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>5560-75</page-range></nlm-citation>
</ref>
<ref id="B10">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Gao]]></surname>
<given-names><![CDATA[J.]]></given-names>
</name>
<name>
<surname><![CDATA[Zheng]]></surname>
<given-names><![CDATA[Z.]]></given-names>
</name>
<name>
<surname><![CDATA[Rawal]]></surname>
<given-names><![CDATA[B.]]></given-names>
</name>
<name>
<surname><![CDATA[Schell]]></surname>
<given-names><![CDATA[M. J.]]></given-names>
</name>
<name>
<surname><![CDATA[Bepler]]></surname>
<given-names><![CDATA[G.]]></given-names>
</name>
<name>
<surname><![CDATA[Haura]]></surname>
<given-names><![CDATA[E. B.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[MIRK/DYRK1B, a novel therapeutic target, mediates cell survival in non-small cell lung cancer cells]]></article-title>
<source><![CDATA[Cancer Biology &amp; Therapy]]></source>
<year>2009</year>
<volume>8</volume>
<numero>17</numero>
<issue>17</issue>
<page-range>1671-9</page-range></nlm-citation>
</ref>
<ref id="B11">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Gong]]></surname>
<given-names><![CDATA[Y.]]></given-names>
</name>
<name>
<surname><![CDATA[Wang]]></surname>
<given-names><![CDATA[J.]]></given-names>
</name>
<name>
<surname><![CDATA[Huo]]></surname>
<given-names><![CDATA[L.]]></given-names>
</name>
<name>
<surname><![CDATA[Wei]]></surname>
<given-names><![CDATA[W.]]></given-names>
</name>
<name>
<surname><![CDATA[Ueno]]></surname>
<given-names><![CDATA[N. T.]]></given-names>
</name>
<name>
<surname><![CDATA[Woodward]]></surname>
<given-names><![CDATA[W. A.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Aldehyde dehydrogenase 1 expression in inflammatory breast cancer as measured by immunohistochemical staining]]></article-title>
<source><![CDATA[Clinical Breast Cancer]]></source>
<year>2014</year>
<volume>14</volume>
<numero>3</numero>
<issue>3</issue>
</nlm-citation>
</ref>
<ref id="B12">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[He]]></surname>
<given-names><![CDATA[M.]]></given-names>
</name>
<name>
<surname><![CDATA[Gu]]></surname>
<given-names><![CDATA[J.]]></given-names>
</name>
<name>
<surname><![CDATA[Zhu]]></surname>
<given-names><![CDATA[J.]]></given-names>
</name>
<name>
<surname><![CDATA[Wang]]></surname>
<given-names><![CDATA[X.]]></given-names>
</name>
<name>
<surname><![CDATA[Wang]]></surname>
<given-names><![CDATA[C.]]></given-names>
</name>
<name>
<surname><![CDATA[Duan]]></surname>
<given-names><![CDATA[C.]]></given-names>
</name>
<name>
<surname><![CDATA[Li]]></surname>
<given-names><![CDATA[J.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Up-regulation of DYRK1B promote astrocyte activation following lipopolysaccharide-induced neuroinflammation]]></article-title>
<source><![CDATA[Neuropeptides]]></source>
<year>2018</year>
<volume>69</volume>
<numero>April</numero>
<issue>April</issue>
<page-range>76-83</page-range></nlm-citation>
</ref>
<ref id="B13">
<nlm-citation citation-type="">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Huangfu]]></surname>
<given-names><![CDATA[D.]]></given-names>
</name>
<name>
<surname><![CDATA[Anderson]]></surname>
<given-names><![CDATA[K. V.]]></given-names>
</name>
</person-group>
<source><![CDATA[Signaling from Smo to Ci / Gli : conservation and divergence of Hedgehog pathways from Drosophila to vertebrates]]></source>
<year>2005</year>
<page-range>3-14</page-range></nlm-citation>
</ref>
<ref id="B14">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Jelski]]></surname>
<given-names><![CDATA[W.]]></given-names>
</name>
<name>
<surname><![CDATA[Laniewska-Dunaj]]></surname>
<given-names><![CDATA[M.]]></given-names>
</name>
<name>
<surname><![CDATA[Orywal]]></surname>
<given-names><![CDATA[K.]]></given-names>
</name>
<name>
<surname><![CDATA[Kochanowicz]]></surname>
<given-names><![CDATA[J.]]></given-names>
</name>
<name>
<surname><![CDATA[Rutkowski]]></surname>
<given-names><![CDATA[R.]]></given-names>
</name>
<name>
<surname><![CDATA[Szmitkowski]]></surname>
<given-names><![CDATA[M.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[The Activity of Alcohol Dehydrogenase (ADH) Isoenzymes and Aldehyde Dehydrogenase (ALDH) in the Sera of Patients with Brain Cancer]]></article-title>
<source><![CDATA[Neurochemical Research]]></source>
<year>2014</year>
<volume>39</volume>
<numero>12</numero>
<issue>12</issue>
<page-range>2313-8</page-range></nlm-citation>
</ref>
<ref id="B15">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Jin]]></surname>
<given-names><![CDATA[K.]]></given-names>
</name>
<name>
<surname><![CDATA[Park]]></surname>
<given-names><![CDATA[S.]]></given-names>
</name>
<name>
<surname><![CDATA[Ewton]]></surname>
<given-names><![CDATA[D. Z.]]></given-names>
</name>
<name>
<surname><![CDATA[Friedman]]></surname>
<given-names><![CDATA[E.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[The survival kinase MIRK/DYRK1B is a downstream effector of oncogenic K-ras in pancreatic cancer]]></article-title>
<source><![CDATA[Cancer Research]]></source>
<year>2007</year>
<volume>67</volume>
<numero>15</numero>
<issue>15</issue>
<page-range>7247-55</page-range></nlm-citation>
</ref>
<ref id="B16">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Kalantari]]></surname>
<given-names><![CDATA[E.]]></given-names>
</name>
<name>
<surname><![CDATA[Saadi]]></surname>
<given-names><![CDATA[F. H.]]></given-names>
</name>
<name>
<surname><![CDATA[Asgari]]></surname>
<given-names><![CDATA[M.]]></given-names>
</name>
<name>
<surname><![CDATA[Shariftabrizi]]></surname>
<given-names><![CDATA[A.]]></given-names>
</name>
<name>
<surname><![CDATA[Roudi]]></surname>
<given-names><![CDATA[R.]]></given-names>
</name>
<name>
<surname><![CDATA[Madjd]]></surname>
<given-names><![CDATA[Z.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Increased Expression of ALDH1A1 in Prostate Cancer is Correlated With Tumor Aggressiveness: A Tissue Microarray Study of Iranian Patients]]></article-title>
<source><![CDATA[Applied Immunohistochemistry &amp; Molecular Morphology: AIMM / Official Publication of the Society for Applied Immunohistochemistry]]></source>
<year>2016</year>
<volume>00</volume>
<numero>00</numero>
<issue>00</issue>
<page-range>1-7</page-range></nlm-citation>
</ref>
<ref id="B17">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Kirwan]]></surname>
<given-names><![CDATA[J. A.]]></given-names>
</name>
<name>
<surname><![CDATA[Weber]]></surname>
<given-names><![CDATA[R. J. M.]]></given-names>
</name>
<name>
<surname><![CDATA[Broadhurst]]></surname>
<given-names><![CDATA[D. I.]]></given-names>
</name>
<name>
<surname><![CDATA[Viant]]></surname>
<given-names><![CDATA[M. R.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Direct infusion mass spectrometry metabolomics dataset: A benchmark for data processing and quality control]]></article-title>
<source><![CDATA[Scientific Data]]></source>
<year>2014</year>
<volume>1</volume>
<page-range>1-13</page-range></nlm-citation>
</ref>
<ref id="B18">
<nlm-citation citation-type="">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Liu]]></surname>
<given-names><![CDATA[X. Y.]]></given-names>
</name>
<name>
<surname><![CDATA[Xu]]></surname>
<given-names><![CDATA[X. X.]]></given-names>
</name>
<name>
<surname><![CDATA[Yin]]></surname>
<given-names><![CDATA[X. L.]]></given-names>
</name>
<name>
<surname><![CDATA[Zhang]]></surname>
<given-names><![CDATA[X. X.]]></given-names>
</name>
<name>
<surname><![CDATA[Li]]></surname>
<given-names><![CDATA[X. L.]]></given-names>
</name>
<name>
<surname><![CDATA[Lu]]></surname>
<given-names><![CDATA[X. H.]]></given-names>
</name>
</person-group>
<source><![CDATA[Relationship between Glioblastoma Heterogeneity and Survival Time: An MR Imaging Texture Analysis]]></source>
<year>2017</year>
<page-range>1-7</page-range></nlm-citation>
</ref>
<ref id="B19">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Louis]]></surname>
<given-names><![CDATA[D. N.]]></given-names>
</name>
<name>
<surname><![CDATA[Holland]]></surname>
<given-names><![CDATA[E. C.]]></given-names>
</name>
<name>
<surname><![CDATA[Cairncross]]></surname>
<given-names><![CDATA[J. G.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Glioma classification: A molecular reappraisal]]></article-title>
<source><![CDATA[The American Journal of Pathology]]></source>
<year>2001</year>
<volume>159</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>779-86</page-range></nlm-citation>
</ref>
<ref id="B20">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Louis]]></surname>
<given-names><![CDATA[D. N.]]></given-names>
</name>
<name>
<surname><![CDATA[Perry]]></surname>
<given-names><![CDATA[A.]]></given-names>
</name>
<name>
<surname><![CDATA[Reifenberger]]></surname>
<given-names><![CDATA[G.]]></given-names>
</name>
<name>
<surname><![CDATA[Deimling]]></surname>
<given-names><![CDATA[A. Von]]></given-names>
</name>
<name>
<surname><![CDATA[Figarella]]></surname>
<given-names><![CDATA[D.]]></given-names>
</name>
<name>
<surname><![CDATA[Webster]]></surname>
<given-names><![CDATA[B.]]></given-names>
</name>
<name>
<surname><![CDATA[Ellison]]></surname>
<given-names><![CDATA[D. W.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary]]></article-title>
<source><![CDATA[Acta Neuropathologica]]></source>
<year>2016</year>
</nlm-citation>
</ref>
<ref id="B21">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Megger]]></surname>
<given-names><![CDATA[D. A.]]></given-names>
</name>
<name>
<surname><![CDATA[Padden]]></surname>
<given-names><![CDATA[J.]]></given-names>
</name>
<name>
<surname><![CDATA[Rosowski]]></surname>
<given-names><![CDATA[K.]]></given-names>
</name>
<name>
<surname><![CDATA[Uszkoreit]]></surname>
<given-names><![CDATA[J.]]></given-names>
</name>
<name>
<surname><![CDATA[Bracht]]></surname>
<given-names><![CDATA[T.]]></given-names>
</name>
<name>
<surname><![CDATA[Eisenacher]]></surname>
<given-names><![CDATA[M.]]></given-names>
</name>
<name>
<surname><![CDATA[Sitek]]></surname>
<given-names><![CDATA[B.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[One Sample, One Shot - Evaluation of sample preparation protocols for the mass spectrometric proteome analysis of human bile fluid without extensive fractionation]]></article-title>
<source><![CDATA[Journal of Proteomics]]></source>
<year>2017</year>
<volume>154</volume>
<page-range>13-21</page-range></nlm-citation>
</ref>
<ref id="B22">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Natsume]]></surname>
<given-names><![CDATA[A. Y. J.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Gene therapy for high-grade glioma: current approaches and future directions]]></article-title>
<source><![CDATA[Cell Adhes Migr]]></source>
<year>2008</year>
<volume>2</volume>
</nlm-citation>
</ref>
<ref id="B23">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Olmez]]></surname>
<given-names><![CDATA[I.]]></given-names>
</name>
<name>
<surname><![CDATA[Shen]]></surname>
<given-names><![CDATA[W.]]></given-names>
</name>
<name>
<surname><![CDATA[Mcdonald]]></surname>
<given-names><![CDATA[H.]]></given-names>
</name>
<name>
<surname><![CDATA[Ozpolat]]></surname>
<given-names><![CDATA[B.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Dedifferentiation of patient-derived glioblastoma multiforme cell lines results in a cancer stem cell-like state with mitogen-independent growth]]></article-title>
<source><![CDATA[Journal of Cellular and Molecular Medicine]]></source>
<year>2015</year>
<volume>19</volume>
<numero>6</numero>
<issue>6</issue>
<page-range>1262-1272.</page-range></nlm-citation>
</ref>
<ref id="B24">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Ostrom]]></surname>
<given-names><![CDATA[Q. T.]]></given-names>
</name>
<name>
<surname><![CDATA[Gittleman]]></surname>
<given-names><![CDATA[H.]]></given-names>
</name>
<name>
<surname><![CDATA[Liao]]></surname>
<given-names><![CDATA[P.]]></given-names>
</name>
<name>
<surname><![CDATA[Vecchione-Koval]]></surname>
<given-names><![CDATA[T.]]></given-names>
</name>
<name>
<surname><![CDATA[Wolinsky]]></surname>
<given-names><![CDATA[Y.]]></given-names>
</name>
<name>
<surname><![CDATA[Kruchko]]></surname>
<given-names><![CDATA[C.]]></given-names>
</name>
<name>
<surname><![CDATA[Barnholtz-Sloan]]></surname>
<given-names><![CDATA[J. S.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[CBTRUS Statistical Report: Primary brain and other central nervous system tumors diagnosed in the United States in 2010-2014]]></article-title>
<source><![CDATA[Neuro-Oncology]]></source>
<year>2017</year>
<volume>19</volume>
<numero>suppl_5</numero>
<issue>suppl_5</issue>
<page-range>v1-v88</page-range></nlm-citation>
</ref>
<ref id="B25">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Park]]></surname>
<given-names><![CDATA[M.]]></given-names>
</name>
<name>
<surname><![CDATA[Koo]]></surname>
<given-names><![CDATA[S.]]></given-names>
</name>
<name>
<surname><![CDATA[Jong]]></surname>
<given-names><![CDATA[L.]]></given-names>
</name>
<name>
<surname><![CDATA[Chang]]></surname>
<given-names><![CDATA[H.]]></given-names>
</name>
<name>
<surname><![CDATA[Gu]]></surname>
<given-names><![CDATA[S.]]></given-names>
</name>
<name>
<surname><![CDATA[Eui]]></surname>
<given-names><![CDATA[K.]]></given-names>
</name>
<name>
<surname><![CDATA[Ahn]]></surname>
<given-names><![CDATA[S.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Elderly patients with newly diagnosed glioblastoma: can preoperative imaging descriptors improve the predictive power of a survival model?]]></article-title>
<source><![CDATA[Journal of Neuro-Oncology]]></source>
<year>2017</year>
<page-range>423-31</page-range></nlm-citation>
</ref>
<ref id="B26">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Pérez-Sánchez]]></surname>
<given-names><![CDATA[G.]]></given-names>
</name>
<name>
<surname><![CDATA[Jiménez]]></surname>
<given-names><![CDATA[A.]]></given-names>
</name>
<name>
<surname><![CDATA[Quezada-Ramírez]]></surname>
<given-names><![CDATA[M. A.]]></given-names>
</name>
<name>
<surname><![CDATA[Estudillo]]></surname>
<given-names><![CDATA[E.]]></given-names>
</name>
<name>
<surname><![CDATA[Ayala-Sarmiento]]></surname>
<given-names><![CDATA[A. E.]]></given-names>
</name>
<name>
<surname><![CDATA[Mendoza-Hernández]]></surname>
<given-names><![CDATA[G.]]></given-names>
</name>
<name>
<surname><![CDATA[Segovia]]></surname>
<given-names><![CDATA[J.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Annexin A1, Annexin A2, and DYRK1B are upregulated during GAS1-induced cell cycle arrest]]></article-title>
<source><![CDATA[Journal of Cellular Physiology]]></source>
<year>2018</year>
<volume>233</volume>
<numero>5</numero>
<issue>5</issue>
<page-range>4166-82</page-range></nlm-citation>
</ref>
<ref id="B27">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Rasper]]></surname>
<given-names><![CDATA[M.]]></given-names>
</name>
<name>
<surname><![CDATA[Schäfer]]></surname>
<given-names><![CDATA[A.]]></given-names>
</name>
<name>
<surname><![CDATA[Piontek]]></surname>
<given-names><![CDATA[G.]]></given-names>
</name>
<name>
<surname><![CDATA[Teufel]]></surname>
<given-names><![CDATA[J.]]></given-names>
</name>
<name>
<surname><![CDATA[Brockhoff]]></surname>
<given-names><![CDATA[G.]]></given-names>
</name>
<name>
<surname><![CDATA[Ringel]]></surname>
<given-names><![CDATA[F.]]></given-names>
</name>
<name>
<surname><![CDATA[Schlegel]]></surname>
<given-names><![CDATA[J.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Aldehyde dehydrogenase 1 positive glioblastoma cells show brain tumor stem cell capacity]]></article-title>
<source><![CDATA[Neuro-Oncology]]></source>
<year>2010</year>
<volume>12</volume>
<numero>10</numero>
<issue>10</issue>
<page-range>1024-33</page-range></nlm-citation>
</ref>
<ref id="B28">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Schäfer]]></surname>
<given-names><![CDATA[A.]]></given-names>
</name>
<name>
<surname><![CDATA[Teufel]]></surname>
<given-names><![CDATA[J.]]></given-names>
</name>
<name>
<surname><![CDATA[Ringel]]></surname>
<given-names><![CDATA[F.]]></given-names>
</name>
<name>
<surname><![CDATA[Bettstetter]]></surname>
<given-names><![CDATA[M.]]></given-names>
</name>
<name>
<surname><![CDATA[Hoepner]]></surname>
<given-names><![CDATA[I.]]></given-names>
</name>
<name>
<surname><![CDATA[Rasper]]></surname>
<given-names><![CDATA[M.]]></given-names>
</name>
<name>
<surname><![CDATA[Schlegel]]></surname>
<given-names><![CDATA[J.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Aldehyde dehydrogenase 1A1-a new mediator of resistance to temozolomide in glioblastoma]]></article-title>
<source><![CDATA[Neuro-Oncology]]></source>
<year>2012</year>
<volume>14</volume>
<numero>12</numero>
<issue>12</issue>
<page-range>1452-64</page-range></nlm-citation>
</ref>
<ref id="B29">
<nlm-citation citation-type="">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Strober]]></surname>
<given-names><![CDATA[W.]]></given-names>
</name>
</person-group>
<source><![CDATA[Trypan Blue Exclusion Test of Cell Viability]]></source>
<year>2015</year>
<volume>November</volume>
<page-range>3-5</page-range></nlm-citation>
</ref>
<ref id="B30">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Stupp]]></surname>
<given-names><![CDATA[R.]]></given-names>
</name>
<name>
<surname><![CDATA[Roila]]></surname>
<given-names><![CDATA[F.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Malignant glioma: ESMO clinical recommendations for diagnosis, treatment and follow-up]]></article-title>
<source><![CDATA[Annals of Oncology]]></source>
<year>2009</year>
<volume>20</volume>
<numero>SUPPL. 4</numero>
<issue>SUPPL. 4</issue>
<page-range>126-8</page-range></nlm-citation>
</ref>
<ref id="B31">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Tomita]]></surname>
<given-names><![CDATA[H.]]></given-names>
</name>
<name>
<surname><![CDATA[Tanaka]]></surname>
<given-names><![CDATA[K.]]></given-names>
</name>
<name>
<surname><![CDATA[Tanaka]]></surname>
<given-names><![CDATA[T.]]></given-names>
</name>
<name>
<surname><![CDATA[Hara]]></surname>
<given-names><![CDATA[A.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Aldehyde dehydrogenase 1A1 in stem cells and cancer]]></article-title>
<source><![CDATA[Oncotarget]]></source>
<year>2016</year>
<volume>7</volume>
<numero>10</numero>
<issue>10</issue>
<page-range>11018-32</page-range></nlm-citation>
</ref>
<ref id="B32">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Van Den Bent]]></surname>
<given-names><![CDATA[M. J.]]></given-names>
</name>
<name>
<surname><![CDATA[Weller]]></surname>
<given-names><![CDATA[M.]]></given-names>
</name>
<name>
<surname><![CDATA[Wen]]></surname>
<given-names><![CDATA[P. Y.]]></given-names>
</name>
<name>
<surname><![CDATA[Kros]]></surname>
<given-names><![CDATA[J. M.]]></given-names>
</name>
<name>
<surname><![CDATA[Aldape]]></surname>
<given-names><![CDATA[K.]]></given-names>
</name>
<name>
<surname><![CDATA[Chang]]></surname>
<given-names><![CDATA[S.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[A clinical perspective on the 2016 WHO brain tumor classification and routine molecular diagnostics]]></article-title>
<source><![CDATA[Neuro-Oncology]]></source>
<year>2017</year>
<volume>19</volume>
<numero>5</numero>
<issue>5</issue>
<page-range>614-24</page-range></nlm-citation>
</ref>
<ref id="B33">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Visus]]></surname>
<given-names><![CDATA[C.]]></given-names>
</name>
<name>
<surname><![CDATA[Ito]]></surname>
<given-names><![CDATA[D.]]></given-names>
</name>
<name>
<surname><![CDATA[Amoscato]]></surname>
<given-names><![CDATA[A.]]></given-names>
</name>
<name>
<surname><![CDATA[Maciejewska-Franczak]]></surname>
<given-names><![CDATA[M.]]></given-names>
</name>
<name>
<surname><![CDATA[Abdelsalem]]></surname>
<given-names><![CDATA[A.]]></given-names>
</name>
<name>
<surname><![CDATA[Dhir]]></surname>
<given-names><![CDATA[R.]]></given-names>
</name>
<name>
<surname><![CDATA[DeLeo]]></surname>
<given-names><![CDATA[A. B.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Identification of human aldehyde dehydrogenase 1 family member a1 as a novel CD8+ T-cell-defined tumor antigen in squamous cell carcinoma of the head and neck]]></article-title>
<source><![CDATA[Cancer Research]]></source>
<year>2007</year>
<volume>67</volume>
<numero>21</numero>
<issue>21</issue>
<page-range>10538-45</page-range></nlm-citation>
</ref>
<ref id="B34">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Vilenchik]]></surname>
<given-names><![CDATA[M.]]></given-names>
</name>
<name>
<surname><![CDATA[Kuznetsova]]></surname>
<given-names><![CDATA[A.]]></given-names>
</name>
<name>
<surname><![CDATA[Frid]]></surname>
<given-names><![CDATA[M.]]></given-names>
</name>
<name>
<surname><![CDATA[Duey]]></surname>
<given-names><![CDATA[M.]]></given-names>
</name>
<name>
<surname><![CDATA[Damiani]]></surname>
<given-names><![CDATA[A.]]></given-names>
</name>
<name>
<surname><![CDATA[De Leon]]></surname>
<given-names><![CDATA[L.]]></given-names>
</name>
<name>
<surname><![CDATA[Potapova]]></surname>
<given-names><![CDATA[O.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Implication of DYRK1B kinase in dormant glioblastoma cancers and utilization of DYRK1B inhibitors as a novel therapeutic strategy for glioblastoma]]></article-title>
<source><![CDATA[Journal of Clinical Oncology]]></source>
<year>2019</year>
<volume>37</volume>
<numero>15_suppl</numero>
<issue>15_suppl</issue>
<page-range>e14670</page-range></nlm-citation>
</ref>
<ref id="B35">
<nlm-citation citation-type="">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Wang]]></surname>
<given-names><![CDATA[Y.]]></given-names>
</name>
<name>
<surname><![CDATA[Wang]]></surname>
<given-names><![CDATA[W.]]></given-names>
</name>
<name>
<surname><![CDATA[Chen]]></surname>
<given-names><![CDATA[Z.]]></given-names>
</name>
</person-group>
<source><![CDATA[Expression of Aldehyde Dehydrogenase 1A1 (ALDH1A1) as a Prognostic Biomarker in Colorectal Cancer Using Immunohistochemistry]]></source>
<year>2018</year>
<page-range>2864-72</page-range></nlm-citation>
</ref>
<ref id="B36">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Wen]]></surname>
<given-names><![CDATA[P.]]></given-names>
</name>
<name>
<surname><![CDATA[Kesari]]></surname>
<given-names><![CDATA[S.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Malignant gliomas in adults]]></article-title>
<source><![CDATA[The New England Journal of Medical]]></source>
<year>2008</year>
<volume>359</volume>
<numero>5</numero>
<issue>5</issue>
<page-range>492-507</page-range></nlm-citation>
</ref>
<ref id="B37">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Xu]]></surname>
<given-names><![CDATA[S. L.]]></given-names>
</name>
<name>
<surname><![CDATA[Liu]]></surname>
<given-names><![CDATA[S.]]></given-names>
</name>
<name>
<surname><![CDATA[Cui]]></surname>
<given-names><![CDATA[W.]]></given-names>
</name>
<name>
<surname><![CDATA[Shi]]></surname>
<given-names><![CDATA[Y.]]></given-names>
</name>
<name>
<surname><![CDATA[Liu]]></surname>
<given-names><![CDATA[Q.]]></given-names>
</name>
<name>
<surname><![CDATA[Duan]]></surname>
<given-names><![CDATA[J. J.]]></given-names>
</name>
<name>
<surname><![CDATA[Bian]]></surname>
<given-names><![CDATA[X. W.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Aldehyde dehydrogenase 1A1 circumscribes high invasive glioma cells and predicts poor prognosis]]></article-title>
<source><![CDATA[American Journal of Cancer Research]]></source>
<year>2015</year>
<volume>5</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>1471-83</page-range></nlm-citation>
</ref>
<ref id="B38">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Yue]]></surname>
<given-names><![CDATA[L.]]></given-names>
</name>
<name>
<surname><![CDATA[Huang]]></surname>
<given-names><![CDATA[Z. M.]]></given-names>
</name>
<name>
<surname><![CDATA[Fong]]></surname>
<given-names><![CDATA[S.]]></given-names>
</name>
<name>
<surname><![CDATA[Leong]]></surname>
<given-names><![CDATA[S.]]></given-names>
</name>
<name>
<surname><![CDATA[Jakowatz]]></surname>
<given-names><![CDATA[J. G.]]></given-names>
</name>
<name>
<surname><![CDATA[Charruyer-Reinwald]]></surname>
<given-names><![CDATA[A.]]></given-names>
</name>
<name>
<surname><![CDATA[Ghadially]]></surname>
<given-names><![CDATA[R.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Targeting ALDH1 to decrease tumorigenicity, growth and metastasis of human melanoma]]></article-title>
<source><![CDATA[Melanoma Research]]></source>
<year>2015</year>
<volume>25</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>138-48</page-range></nlm-citation>
</ref>
<ref id="B39">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Zhang]]></surname>
<given-names><![CDATA[Q.]]></given-names>
</name>
<name>
<surname><![CDATA[Taguchi]]></surname>
<given-names><![CDATA[A.]]></given-names>
</name>
<name>
<surname><![CDATA[Schliekelman]]></surname>
<given-names><![CDATA[M.]]></given-names>
</name>
<name>
<surname><![CDATA[Wong]]></surname>
<given-names><![CDATA[C.-H.]]></given-names>
</name>
<name>
<surname><![CDATA[Chin]]></surname>
<given-names><![CDATA[A.]]></given-names>
</name>
<name>
<surname><![CDATA[Kuick]]></surname>
<given-names><![CDATA[R.]]></given-names>
</name>
<name>
<surname><![CDATA[Hanash]]></surname>
<given-names><![CDATA[S.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Comprehensive Proteomic Profiling of Aldehyde Dehydrogenases in Lung Adenocarcinoma Cell Lines]]></article-title>
<source><![CDATA[International Journal of Proteomics]]></source>
<year>2011</year>
<volume>2011</volume>
<page-range>1-8</page-range></nlm-citation>
</ref>
<ref id="B40">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Zhou]]></surname>
<given-names><![CDATA[Q.]]></given-names>
</name>
<name>
<surname><![CDATA[Phoa]]></surname>
<given-names><![CDATA[A. F.]]></given-names>
</name>
<name>
<surname><![CDATA[Abbassi]]></surname>
<given-names><![CDATA[R. H.]]></given-names>
</name>
<name>
<surname><![CDATA[Hoque]]></surname>
<given-names><![CDATA[M.]]></given-names>
</name>
<name>
<surname><![CDATA[Reekie]]></surname>
<given-names><![CDATA[T. A.]]></given-names>
</name>
<name>
<surname><![CDATA[Font]]></surname>
<given-names><![CDATA[J. S.]]></given-names>
</name>
<name>
<surname><![CDATA[Kassiou]]></surname>
<given-names><![CDATA[M.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Structural Optimization and Pharmacological Evaluation of Inhibitors Targeting Dual-Specificity Tyrosine Phosphorylation-Regulated Kinases (DYRK) and CDC-like kinases (CLK) in Glioblastoma]]></article-title>
<source><![CDATA[Journal of Medicinal Chemistry]]></source>
<year>2017</year>
<volume>60</volume>
<numero>5</numero>
<issue>5</issue>
<page-range>2052-70</page-range></nlm-citation>
</ref>
</ref-list>
</back>
</article>
